Expanding the Reach: TAR-200 in Papillary Disease and Beyond
Автор: GU Oncology Now
Загружено: 2025-09-15
Просмотров: 89
In this video series, co-researchers of the Phase IIb SunRISe-1 study Joseph Jacob, MD, SUNY Upstate Medical University, and Sia Daneshmand, MD, University of Southern California, discuss the development, efficacy, and safety of the TAR-200 intravesical drug delivery device for non-muscle invasive bladder cancer. They explore early clinical experiences, durable responses, insights from combination therapy, and the expanding role of TAR-200 in papillary disease and real-world clinical practice.
In the final segment, they highlight emerging results from papillary-only cohorts and discuss the broader potential for TAR-200 beyond CIS. They emphasize its ease of use, favorable safety profile, and anticipated integration into clinical practice as regulatory approval approaches.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
